Trastuzumab emtansine (Kadcyla®) is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.
|25/09/2013||24/10/2013||Full Pharmacoeconomic Evaluation recommended|
|05/02/2014||30/06/2014||Reimbursement not Recommended|
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.